Inhibition of DNA demethylation attenuates experimental necrotizing enterocolitis via suppression of TLR4-mediated inflammation

Technical Summary: Inhibition of DNA Demethylation Attenuates Experimental Necrotizing Enterocolitis via Suppression of TLR4-Mediated Inflammation

Problem Statement
Necrotizing enterocolitis (NEC) is a severe, often fatal inflammatory bowel disease affecting preterm infants, characterized by intestinal epithelial injury, necrosis, and high mortality rates. While excessive inflammatory signaling is a known driver of tissue injury, the molecular mechanisms regulating inflammatory susceptibility remain incompletely understood. Previous research has linked epigenetic modifications, specifically DNA methylation, to NEC development, noting widespread hypermethylation in human NEC tissue. However, the role of active DNA demethylation—mediated by ten-eleven translocation (TET) enzymes—and its potential as a therapeutic target in NEC has not been fully investigated.

Methodology
The study employed a multi-platform approach combining in vivo mouse models and in vitro human and murine cell systems to investigate DNA methylation dynamics and demethylation inhibition in NEC.

• In Vivo Models:

  • Experimental NEC: Neonatal C57BL/6J mice (Postnatal Day 4) were assigned to breast milk-fed controls (BF) or formula-fed groups exposed to NEC-associated dysbiotic bacteria and intermittent hypoxia (FF). A subset of FF mice received daily intraperitoneal injections of Bobcat339, a specific TET inhibitor, from PND4 to PND6.
  • Endotoxemia Model: PND7 neonatal mice were injected with lipopolysaccharide (LPS) to induce inflammation, with or without Bobcat339 treatment.
  • Analysis: Ileal tissues were harvested for histological examination (H&E, TUNEL for apoptosis), immunofluorescence (5-mC, 5-hmC, O-GlcNAc, cleaved caspase-3), and quantitative real-time PCR (qRT-PCR) for gene expression.

• In Vitro Models:

  • Enteroids: Mouse and human neonatal ileal enteroids were cultured in an "apical-out" configuration ("NEC-in-a-dish") and exposed to NEC-associated bacteria or LPS, with or without Bobcat339.
  • Macrophages: RAW264.7 mouse macrophages were exposed to NEC-associated bacteria or LPS with or without Bobcat339.
  • Assays: Gene expression of inflammatory mediators (e.g., Il1b, Tnfa, Lcn2, iNOS) was measured via qRT-PCR.

Key Contributions and Results

1. Suppression of Active DNA Demethylation in NEC:
   The study established that experimental NEC is characterized by a disruption in the active DNA demethylation pathway. Compared to breast milk-fed controls, NEC mice exhibited:

   • Significantly reduced mRNA expression of Tet1 and Tet2 (but not Tet3).
   • Reduced expression of Ogt (O-GlcNAc transferase), which interacts with TET proteins.
   • Decreased global levels of 5-hydroxymethylcytosine (5-hmC) and increased levels of 5-methylcytosine (5-mC), indicating global DNA hypermethylation.
   • Reduced O-GlcNAcylation in the intestinal epithelium.

2. Therapeutic Efficacy of TET Inhibition:
   Pharmacologic inhibition of DNA demethylation using Bobcat339 significantly attenuated NEC severity in neonatal mice. Treated mice showed:

   • Preservation of villus architecture and reduced mucosal destruction.
   • Marked reduction in epithelial apoptosis (decreased TUNEL and cleaved caspase-3 staining).
   • Significant downregulation of pro-inflammatory mediators, including Il1b, Tnfa, Lcn2, and Cxcl1.

3. Mechanism via TLR4 Signaling:
   The protective effects of Bobcat339 were linked to the suppression of Toll-like receptor 4 (TLR4)-mediated inflammation.

   • In an LPS-induced endotoxemia model, Bobcat339 reduced apoptosis and inflammation, mirroring the NEC findings.
   • LPS exposure itself was found to decrease Tet1/2/3 expression, suggesting a feedback loop where inflammation alters demethylation capacity.
   • In vitro experiments confirmed that Bobcat339 directly suppressed cytokine induction (Il1b, Tnfa, iNOS) in both mouse enteroids and macrophages exposed to bacterial stimuli or LPS.
   • Human neonatal enteroids similarly showed reduced cytokine induction upon Bobcat339 treatment, confirming translational relevance.

Significance and Claims
The authors conclude that dysregulated DNA demethylation is a novel contributor to NEC pathogenesis. Specifically, the study posits that:

• Experimental NEC involves the suppression of TET enzymes and the OGT-TET axis, leading to global DNA hypermethylation.
• Active DNA demethylation appears to facilitate TLR4-driven inflammatory responses, potentially by increasing chromatin accessibility at TLR4 regulatory regions.
• Inhibiting DNA demethylation (via Bobcat339) dampens TLR4-mediated immune responses and intestinal inflammation, thereby attenuating tissue injury.
• Targeting epigenetic demethylation pathways represents a promising therapeutic strategy for NEC, distinct from current supportive care or antibiotic treatments.

The paper maintains a cautious tone regarding the mechanism, noting that while functional data strongly supports epigenetic regulation upstream of TLR4, locus-specific methylation analysis of the TLR4 promoter was not performed. Furthermore, the authors acknowledge that TET enzymes have context-dependent roles in immunity and that long-term safety of TET inhibition in neonates requires further evaluation. However, within the specific context of neonatal intestinal inflammation, the data suggests that active DNA demethylation amplifies injury, and its inhibition offers a potential avenue for disease mitigation.